China Resources Pharmaceutical Group Limited (HKEX: 3320) reported that its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), released unaudited preliminary financial data for the year ended 31 December 2025. CR Sanjiu is 63.22% indirectly owned by China Resources Pharmaceutical Group.

According to the announcement, CR Sanjiu recorded total operating revenue of RMB31.629 billion, marking a 14.53% year-on-year increase. Net profit attributable to shareholders reached RMB3.422 billion, up 1.60% year-on-year. At the end of 2025, total assets rose to RMB58.807 billion, largely attributed to the acquisition of Tasly Pharmaceutical Group Co., Ltd. during the reporting period. Share capital expanded by 29.58% compared to the beginning of the period, and net assets per share attributable to shareholders declined by 14.06% to RMB13.32 due to the higher share base.

The aforementioned figures are based on unaudited financial statements prepared under PRC Generally Accepted Accounting Principles. Final audited results will be disclosed in CR Sanjiu’s 2025 annual report. The information pertains solely to CR Sanjiu and does not offer a comprehensive picture of the overall operations or financial condition of the broader group. Shareholders and potential investors are advised to exercise caution when interpreting these data points.